参考文献 [1]Barditch-crovop.P,Toole.J,Hendrix C.W,e al.1996.Anti-human immunodeficiency virus(HIV) activity,safety,and pharmacokinetics of adevoxil(9-[2-(bis pivaloyloxymethyl)phosphonylmethoxyethyl]adenine) in HIV infected patients.J.Infect Dis 1997;176;406-413. [2]Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller MD, Cherrington JM, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D, Toole JJ and Coakley D (1999) Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. J Am Med Assoc 282: 2305-2312. [3]Balzarini, J., and E. De Clercq. 1991. 5-Phosphoribosyl-1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives. J. Biol. Chem. 266:8686-8689 [4]Balzarini, J., Z. Hao, P. Herdewijn, D. G. Johns, and E. DeClerq. 1991. Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. USA 88:1499-1503 [5]Seigneres, B., S. Aguesse-Germon, C. Pichoud, I. Vuillermoz, C. Jamard, C. Trepo, and F. Zoulim. 2001. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J. Hepatol.34:114-122. [6]Xiong, XF, C Flores, H Yang, JJ Toole, and C. S. Gibbs. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673 [7]Cherrington, J. M., S. J. W. Allen, N. Bischofberger, and M. S. Chen. 1995. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases and Antivir. Chem. Chemother. 6:217-221. [8]Calio, R., N. Villani, E. Balestra, F. Sesa, A. Holy, J. Balzarini, E. De Clercq, C. F. Perno, and V. Del Gobbo. 1994. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antivir. Res. 23:77-89. [9]Cooksley.H,Chokshi.S,Wedemeyer.H,et al. Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil treatment :a multicenter,controlled study.Gilead Abstracts,At the 37th Annual Meeting of the European Association for the Study of the Liver(EASL) . [10]Kearney.B,Knight.W,Currie.G,etc, Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjects. see 20.. [11]Neumann.A.U,Havlin.Y,Ronen.T, etc,Long-term hepatitis B virus kinetics classification during treatment with adefovir dipivoxil. see 20. [12]Hadziyannis.S,Tassopoulos.N,Heathcote.J,Chang.T.T, etc GS-98-438,Adouble-blind,randomized, placebo -controlled study of adefovir dipivoxil for precore mutant chronic hepatitis B:48-week result.see 20. [13]Marcellin P,Chang TT,Lim SG,et al.A double-blind,randomized,placebo-controllde study of adefovir dipivoxil for the treatment of patients with HBeAg+chronic hepatitis B infection:48 week results. .Hepatology .2001;34:340A Abstract674. [14]Heathcote..E.J,Jdffers.L,Perrillo.R,etc, Sustained antiviral response and lack of viral resistance with long-term adefovir dipivoxil therapy in chronic hepatitis B virus infection. see 20. [15]Westland.C,Delaney.W,Yang.H,Fry.J,etc, Distribution and clinical response of hepatitis B virus genotypes in phase III studies of adefovir dipivoxil. see 20. [16]Peter.M,Hann.H.W,Martin.P,etc, Adefovir dipivoxil alone and in combination with lamivudine suppresses lamivudine-resistant hepatitis B virus replication :16-week interima analysis. see 20.. [17]Marcellin.P,Chang.T.Tlim.S.G,etc, Baseline alanine aminotransferase level predicts histologic and serologic response in patients with HBeAg-positive chronic hepatitis B treated with adefovir dipivoxil . see 20. [18]Westland.C.E,Gibbs.GS,Miller.M,etc,Loss of lamirudine resistance mutations after patients were switched to adefovir dipivoxil therapy. [19]Perrillo R,Schiff E,Yoshida E,et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutations. Hepatology.2000;32:129-134 [20]Benhamou Y,Bochet M,Thibault V, et al.Long-term incidence of hepatitis B virus resistance to lamivudine in human immumodeficiency virus-infected patients.Hepatology.1999;30:1302-1306. [21]Schiff.E,Neuhaus.P,Tillmann.H,et al.. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B infection in post-liver transplant patients. see 20. [22]Yang H,Westland DE,DelaneyWE IV,et al.Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72 to 136 weeks. .Hepatology .2001;34:316A Abstract577. [23]On the net:Food and Drug Administration:http://www.fda.gov [24]Knight.W,Hayashi.S,Benhamou.Y,Currie.G,etc, Dosing guidelines for adefovir dipivoxil in the treatment of hepatitis B virus-infected patients with renal and or hepatic impairment.. see 20.. [25]Kearney.B,Knight.W,Currie.G,etc,etc, A drug-drug interaction study between aderovir dipivoxil and lamivudine,Acetaminophen,Ibuprofen,and Trimethoprim/Sulfamethoxazole. see 20.. [26]Delaney.W,Yang.H,Gibbs.C,Miller.M,Xiong.s.Lamividine-resistant hepatitis Bvirus is cross-resistant to L-dT and L-dC in vitro , see 20. [27]Doo E,Liang TAJ.Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.Gastroenterology.2001;120:1000-1008 [28]Locarnini, S., and C. Birch. 1999. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J. Hepatol. 30:536-550 [29]Julien Delmas,1 Olivier Schorr,1 Catherine Jamard,1 Craig Gibbs,2 Christian Trépo,1 Olivier Hantz,1 and Fabien Zoulim1 Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro Antimicrobial Agents and Chemotherapy, February 2002, p. 425-433, Vol. 46, No. 2 [30]Delaney.IV.W,Yang.H,Miller.N,Gibbs.C,Xiong.S,Combination of adefovir dipivoxil with lanivudine,entacavir,or L-dT produce additive antiviral effects against hepatitis B virus in vitro. see 20.. [31]Colledge, D., G. Civitico, S. Locarnini, and T. Shaw. 2000. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob. Agents Chemother. 44:551-560. [32]Lau, G. K., M. Tsiang, J. Hou, S. Yuen, W. F. Carman, L. Zhang, C. S. Gibbs, and S. Lam. 2000. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 32:394-399 [33]Mason, W. S., J. Cullen, J. Saputelli, T. T. Wu, C. Liu, W. T. London, E. Lustbader, P. Schaffer, A. P. Oconnell, I. Fourel, C. E. Aldrich, and A. R. Jilbert. 1994. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 19:398-411. [34]Guidotti, L. G., R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829. [35]Rollier, C, C. Sunyach, L. Barraud, N. Madani, C. Jamard, C. Trepo, and L. Cova. 1999. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 116:658-665. 【作者单位】100011北京,地坛医院(田梅梅);吉林大学第一医院传染科(牛俊奇、王峰) 【作者简介】 田梅梅,女 硕士 医师 |